NCT05579418View on ClinicalTrials.gov

The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients

PHASE4UnknownINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

October 30, 2024

Study Completion Date

October 30, 2024

Conditions
STEMIDyslipidemias
Interventions
DRUG

Evolocumab

Evolocumab is an injection for management of dyslipidemia

Sponsors
All Listed Sponsors
lead

Hamad Medical Corporation

INDUSTRY

NCT05579418 - The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients | Biotech Hunter | Biotech Hunter